MX2013011092A - Antidotos anticoagulantes. - Google Patents

Antidotos anticoagulantes.

Info

Publication number
MX2013011092A
MX2013011092A MX2013011092A MX2013011092A MX2013011092A MX 2013011092 A MX2013011092 A MX 2013011092A MX 2013011092 A MX2013011092 A MX 2013011092A MX 2013011092 A MX2013011092 A MX 2013011092A MX 2013011092 A MX2013011092 A MX 2013011092A
Authority
MX
Mexico
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
anticoagulants
relates
Prior art date
Application number
MX2013011092A
Other languages
English (en)
Spanish (es)
Inventor
Norbert Hauel
Joanne Van Ryn
Tobias Litzenburger
Keith Canada
Sanjaya Singh
Robert Copenhaver
Christopher Ronald Sarko
Alisa K Waterman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013011092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013011092A publication Critical patent/MX2013011092A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2013011092A 2011-03-30 2012-03-27 Antidotos anticoagulantes. MX2013011092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30
PCT/EP2012/055397 WO2012130834A1 (en) 2011-03-30 2012-03-27 Anticoagulant antidotes

Publications (1)

Publication Number Publication Date
MX2013011092A true MX2013011092A (es) 2013-12-06

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011092A MX2013011092A (es) 2011-03-30 2012-03-27 Antidotos anticoagulantes.

Country Status (23)

Country Link
US (2) US8821871B2 (cg-RX-API-DMAC7.html)
EP (1) EP2691156A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014515740A (cg-RX-API-DMAC7.html)
KR (1) KR20140009437A (cg-RX-API-DMAC7.html)
CN (1) CN103476459A (cg-RX-API-DMAC7.html)
AP (1) AP2013007046A0 (cg-RX-API-DMAC7.html)
AR (1) AR085758A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013025031A2 (cg-RX-API-DMAC7.html)
CA (1) CA2827787A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013002551A1 (cg-RX-API-DMAC7.html)
CO (1) CO6771448A2 (cg-RX-API-DMAC7.html)
EA (1) EA201301090A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012997A (cg-RX-API-DMAC7.html)
IL (1) IL227653A0 (cg-RX-API-DMAC7.html)
MA (1) MA34978B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013011092A (cg-RX-API-DMAC7.html)
PE (1) PE20140964A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501924A1 (cg-RX-API-DMAC7.html)
SG (1) SG193552A1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000388A1 (cg-RX-API-DMAC7.html)
TW (1) TW201302796A (cg-RX-API-DMAC7.html)
UY (1) UY33994A (cg-RX-API-DMAC7.html)
WO (1) WO2012130834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
WO2013082210A1 (en) 2011-11-29 2013-06-06 Perosphere Inc. Anticoagulant reversal agents
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
CN105492446B (zh) * 2013-07-30 2018-08-03 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
EP3060583A1 (en) * 2013-10-25 2016-08-31 Boehringer Ingelheim International GmbH Anticoagulant antidotes
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
CN112272565A (zh) * 2018-04-27 2021-01-26 西雅图儿童医院以西雅图儿童研究机构名义经营 使用慢病毒基因构建体的递送的体内基因疗法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5910573A (en) 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
DK2915564T3 (da) 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
BR112012004169A2 (pt) 2009-08-24 2016-03-29 Boehringer Ingelheim Int intervenções de emergência com carvão vegetal ativado em superdosagem de etexilato de dabigatran
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
WO2012130834A1 (en) 2012-10-04
TN2013000388A1 (en) 2015-01-20
CO6771448A2 (es) 2013-10-15
PH12013501924A1 (en) 2017-10-25
CL2013002551A1 (es) 2014-02-14
MA34978B1 (fr) 2014-03-01
NZ613543A (en) 2015-07-31
PE20140964A1 (es) 2014-08-17
ECSP13012997A (es) 2013-12-31
AR085758A1 (es) 2013-10-23
US8821871B2 (en) 2014-09-02
UY33994A (es) 2012-09-28
JP2014515740A (ja) 2014-07-03
KR20140009437A (ko) 2014-01-22
AP2013007046A0 (en) 2013-08-31
EA201301090A1 (ru) 2014-05-30
US20120276123A1 (en) 2012-11-01
CN103476459A (zh) 2013-12-25
CA2827787A1 (en) 2012-10-04
IL227653A0 (en) 2013-09-30
SG193552A1 (en) 2013-11-29
TW201302796A (zh) 2013-01-16
US20140377265A1 (en) 2014-12-25
BR112013025031A2 (pt) 2017-08-01
EP2691156A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
TN2012000366A1 (en) Anticoagulant antidotes
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
TN2013000388A1 (en) Anticoagulant antidotes
EP2706991A4 (en) IMMUNOGENIC COMPOSITION WITH SEVERAL ANTIGENES, AND METHODS THEREFOR, AND USES THEREOF
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
BR112014030278A2 (pt) anticorpo, e, composição.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
TN2015000050A1 (en) Methods of treating a tauopathy
WO2013021279A3 (en) Highly galactosylated antibodies
HK1218549A1 (zh) 新型抗体框架
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
UY35795A (es) Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
TH1301006508B (th) องค์ประกอบที่รวมถึงโพลีเตตระฟลูออโรเอธิลีน และกระบวนการสำหรับการเตรียมองค์ประกอบของสิ่งนั้น
CL2012001927A1 (es) Anticuerpo capaz de neutralizar la actividad de un anticoagulante de dabigatran; método de fabricación de anticuerpo; kit que comprende al anticuerpo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal